Skip to main content

Genomic Tests Ready For Primetime?

 
8/4/2010:
 
Hello everyone, I am Dr. Muin Khoury, director of the Office of Public Health Genomics at the Centers for Disease Control and Prevention.
You may have heard about different tests. You may even have had patients ask you about these tests or share the results with you.

So why aren't personal genomic tests ready for primetime?

There are 3 key factors that must be considered in the development and evaluation of genetic tests in clinical practice. First, there is the test's analytic validity, which is the test's ability to accurately and reliably measure the thousands of genetic variants on these tests.

In many cases, personal genomic tests do meet quality standards for laboratories. The second thing we have to look at is the clinical validity of these tests, which is the ability of the test to detect or predict particular diseases and health conditions. This is the area for which the data are in so much flux right now.

Most common diseases, as a matter of fact, like diabetes, cancers, and heart disease, are caused by multiple genes and interactions with environment and behavior. More research is needed to identify the full list of variants and how they influence disease susceptibility.

So far, a simple knowledge of family history for disease seems to be a more important risk factor for most common diseases. Genetic variants associated with diseases that have been identified so far typically account for only a small fraction of the measured impact of family history. Therefore, there is a lot of uncertainty about the risk estimates given by these tests; the estimates could rapidly change and [estimates] also vary by patient characteristics such as age, race and ethnicity, and environmental and lifestyle factors.

Finally, there is the most critical issue of the test's clinical utility, which addresses the question of: if a patient is found to be at increased or decreased risk for a disease, what can be done about it? In this area, there is virtually no information available that looks at the health implications of communicating genomic information and the balance of benefits and harms for using these types of tests.


So what advice should providers offer patients?

First, discuss with patients the limitations of personal genomic tests. These tests are not ready for routine use in clinical practice because of their limited clinical validity and clinical utility. Second, encourage patients to collect and keep an updated family health history. Family health history is a very informative and inexpensive "genomic test" that can be used right now. It reflects genes, behaviors, lifestyles, and environmental factors that are shared among relatives..

Family health history can help healthcare providers assess the presence of many genetic conditions and whether patients and their relatives may have an increased risk for specific diseases

And lastly, use the discussion of personal genomic tests and family history as a teachable moment to encourage patients to improve their health. We can reinforce the value of simple health promotion and disease prevention messages about increased physical activity, avoidance of cigarette smoking, improved diet, as well as adoption of medical screenings to help lower risk for specific common diseases regardless of genes.

The promise of genomics in the practice of medicine is great and exciting, but today the use of personal genomic tests is still not ready for prime time.

Thank you for your attention.

Web Resources

Genetic Testing, CDC Office of Public Health Genomics http://www.cdc.gov/genomics/gtesting/index.htm
GeneTests. National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov/sites/GeneTests/?


Comments

Popular posts from this blog

Cancer Survivors

Just read a story about one woman's cancer experience. I bet everyone has a story about what goes through your mind when you are told you have cancer. Her thought were about her stunned family members, one crying and the other in shock. I bet there are quite a few stories that could be qualitatively studied. Those experiences could help nurses better help patients during this time.

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer

Key Points Question    What is the frequency and spectrum of cancer susceptibility gene mutations among patients with colorectal cancer diagnosed at younger than 50 years? Findings    In this cohort study of 450 patients with early-onset colorectal cancer, 72 (16%) had a pathogenic mutation. Panel testing identified mutations in patients that may have otherwise been missed; specifically, 24 of 72 patients (33.3%) who were mutation positive did not meet testing criteria for the gene(s) in which they had a mutation. Meaning    Multigene panel testing should be considered for all patients with early-onset colorectal cancer. Read More:   Prevalence and Spectrum of Gene Mutations and Colorectal Cancer

Preventative Measures for Carriers

Reducing the Risk of Colon Cancer Here are some of the preventive steps you and your doctor can take if your genetic test indicates a risk of developing an inherited cancer: Increased Surveillance Colonoscopy every one to two years beginning at age 20-25 or 5-10 years before the earliest age of a diagnosed colorectal cancer in your family, whichever comes first. Colonoscopy annually after age 40. Preventive Surgery If colon cancer (or an advanced precancerous polyp) is diagnosed in a patient with HNPCC , a full, rather than partial, colectomy is recommended. In carefully selected people, for example, those not willing or able to undergo periodic screening, preventive colectomy may be an option based on a positive genetic test result for HNPCC. Preventive Drug Therapies for Colorectal Cancer: Different drugs for the prevention of colorectal cancer are currently being researched for individuals with HNPCC. None of these drugs are currently approved by the FDA for this purpose. Increa...